Navigation Links
Nerve Damage Can Be Prevented By Xenon Administration During Surgery

Brain damage, a potential post-operative complication following coronary artery bypass grafting (CABG) could be prevented by provision of xenon gas, a new study has found. // The results of this first successful clinical trial can be found in Anesthesiology journal.

The researchers successfully administered xenon gas safely to a group of 12 patients undergoing CABG. This revolutionary technique could eventually pave way for development of new treatments for diseases associated with nerve damage such as stroke, spinal cord and brain injury.

Previous studies had established the effectiveness of xenon in neuroprotection. It inhibits the cascade of events that occur during stroke or brain/spinal cord injury. These events result in irreversible damage to the brain. Xenon, a neuroprotectant was found to inhibit activity of the glutamate receptor that resulted in nerve death. Prof. Nick Franks accidentally discovered this potential of xenon while he was involved in the identification of specific molecular targets related to anesthetic action.

Following demonstration of the feasibility of xenon administration to at risk individuals for development of brain damage, the researchers are keen about initiating a clinical trial to test the effectiveness of xenon in a large group of patients. Through current medical treatments, it is possible to prevent mortality associated with nerve damage; nothing can be done to inhibit nerve damage that causes long-term disability.

Xenon is a naturally occurring gas and no instances of toxicity has so far been reported, that makes it an ideal candidate for use as a neuroprotectant.


'"/>




Page: 1

Related medicine news :

1. Epilepsy Drug Helps Diabetic Nerve Damage
2. World’s First Nerve Stem Cells Produced
3. Children With Epilepsy Can Be Treated With Nerve Stimulation
4. FDA Approved Nerve-Stimulation Therapy Now Available In New York
5. Doctors Finish Mother-To-Son Nerve Surgery
6. Stem Cells From Hair Follicle To Repair Nerve Damage
7. Nerve regeneration for Spinal cord injuries
8. Novel Protein, Staufen2 Important In Maintenance Of Nerve Synapses
9. Dividing Nerve Cells Could Trigger Alzheimers Disease
10. Protein Found to Be Essential For Maintaining Nerve Health
11. Nerve Stimulator for Depression Though Not Effective Was Given Approval
Post Your Comments:
(Date:7/9/2008)..., Barcelona, Spain: New figures on assisted repro... has been an explosion in the use of ICSI (intracy...he 24th annual meeting of the European Society of ...lona heard today (Wednesday). Researchers believe ... too often. , In 2005 the most recent year for ...
(Date:7/8/2008)..., Alexandria, Va.A study conducted in Sweden foun...untry whose wives died from cancer four or five ye...hat their spouse,s cancer was incurable, or they h...life. Eighty-six percent of widowers believed next...ancer is incurable, including 71 percent of the me...
(Date:7/8/2008)... CHICAGO, July 8 /PRNewswire/ -- Last month th...e Improvements for Patient and Providers Act",(H.R...re payments to,physicians and other providers went...ent relationship in great jeopardy., , To view t...ewswire.com/mnr/osteopathic/33934/ , The American...
(Date:7/8/2008)... Heart Failure Study Validates Use of Pharos In...ing Platform to Reduce Healthcare Utilization and ...IELD, Ill., July 8 /PRNewswire/ -- Pharos Innovati...t generation clinical and financial,performance im...platform,announced today the results from the Iow...
Breaking Medicine News(10 mins):Health News:Researcher say that ICSI may be over-used in some countries 2Health News:Researcher say that ICSI may be over-used in some countries 3Health News:Study finds that significant proportion of men told wife's cancer was incurable late or not at all 2Health News:Audio: Medicare Cuts Threaten Access to Health Care for Seniors 2Health News:Iowa Medicaid Demonstration Finds Tel-Assurance(R) Remote Monitoring Platform Improved Health Status and Saved $5 Million 2Health News:Iowa Medicaid Demonstration Finds Tel-Assurance(R) Remote Monitoring Platform Improved Health Status and Saved $5 Million 3
...esident Bhairon Singh Shekhawat Tuesday launched t... aimed at creating awareness on HIV/AIDS// among t..., conceived by the ministry of youth affairs, will...ontrol Organisation (NACO) in collaboration with o...
... will soon become the first province in Canada to ...have died of heart failure//. The provincial agen...ed that changes in guidelines that allowed accepti...atory death (DCD) could potentially expand the pot...
...lson, one of the worst affected in the catastrophi...ome overnight after over three months in hospital/...to return back to the hospital within a few weeks ...nd toes, which have been going black with dry gang...
...ional Institute for Clinical Excellence (Nice) sai...to combat high blood pressure//. Government medic...prescribed are to be replaced with more effective ...was found that beta-blockers though control blood ...
Other Medicine News:Health News:Vice President Launches AIDS Awareness Campaign for Youth 2Health News:Ontario Addresses Shortage of Transplant Organs 2
(Date:7/8/2008)...tudy of Clevudine versus Viread(R) versus Cle...titis B, PRINCETON, N.J., July 8 /PRNewswire-Firs...on AIDS and Viral Hepatitis (ANRS), with the suppo... Sciences, Inc. (Nasdaq: GILD ),has initiated th...(R),(tenofovir disoproxil fumarate) administered s...
(Date:7/7/2008)...resence Includes ANA598 and ANA773 Acting via ...hanisms Conference Call Today at ...all/ -- Anadys Pharmaceuticals,Inc. (Nasdaq: AND...nvestigation of the Toll-Like Receptor-7 (TLR7) me...Based on preclinical pharmacology testing,and the ...
(Date:7/7/2008).../- Light Sciences Oncology, Inc.,(LSO...atients with benign,prostatic hyperplasia (BPH), o...n Therapy(TM) (Litx(TM)), an innovative light-acti...to conduct a 12-patient, Phase I/II,dose-escalatio... as a,40-patient, Phase IIa study in Australia, ex...
(Date:7/7/2008)...ire-FirstCall/ -- GeoVax Labs, Inc. (OTC,Bulletin ...opharmaceutical,company specializing in the preven...rovided an operational update on the company,s pro...clinical trial testing and,plans to proceed into t...e,successful human trials evaluating GeoVax AIDS v...
Breaking Medicine Technology:Pharmasset Announces Initiation of Combination Study of Clevudine and Viread(R) for HBV by French National Agency for Research on AIDS and Viral Hepatitis (ANRS) 2Pharmasset Announces Initiation of Combination Study of Clevudine and Viread(R) for HBV by French National Agency for Research on AIDS and Viral Hepatitis (ANRS) 3Pharmasset Announces Initiation of Combination Study of Clevudine and Viread(R) for HBV by French National Agency for Research on AIDS and Viral Hepatitis (ANRS) 4Anadys Pharmaceuticals Resumes Clinical Investigation of TLR7 Mechanism in HCV 2Anadys Pharmaceuticals Resumes Clinical Investigation of TLR7 Mechanism in HCV 3Anadys Pharmaceuticals Resumes Clinical Investigation of TLR7 Mechanism in HCV 4Anadys Pharmaceuticals Resumes Clinical Investigation of TLR7 Mechanism in HCV 5Light Sciences Oncology Begins Clinical Trials of Litx Therapy in Patients with Enlarged Prostate 2Light Sciences Oncology Begins Clinical Trials of Litx Therapy in Patients with Enlarged Prostate 3GeoVax Reports Progress on Its AIDS Vaccine Technology 2GeoVax Reports Progress on Its AIDS Vaccine Technology 3GeoVax Reports Progress on Its AIDS Vaccine Technology 4GeoVax Reports Progress on Its AIDS Vaccine Technology 5Paradigm shift 3A Switch for programmed cell death promotes spread of glioblastoma 14025 1Paradigm shift 3A Switch for programmed cell death promotes spread of glioblastoma 14025 2Amphibians respond behaviorally to impact of clear cutting 2464 1Amphibians respond behaviorally to impact of clear cutting 2464 2Epigenetic changes discovered in major psychosis 2461 1Epigenetic changes discovered in major psychosis 2461 2Genesis Pharmaceuticals Changes Auditors 14020 1Genesis Pharmaceuticals Changes Auditors 14020 2
...FIELD, Mass.--(BUSINESS WIRE)--Jul 6, 2007 - Busin...race by pharmaceutical and,biotechnology companies...genesis treatment for cardiovascular disease. Whil...fi-Aventis, Boston,Scientific, Baxter, and Genzyme...ising new biological therapy for advanced,coronary...
...DGEWATER, N.J., July 05, 2007 /PRNewswire/ -- Resu...trolled, open-label, Phase,3 study showed that 77 ...ults taking PREZISTA(TM) (darunavir) 600 mg tablet...plus an optimized,background regimen (OBR) of anti...ad of <400 copies/mL at week 48, compared to 68,pe...
Other Medicine Technology:BusinessWeek Article Highlights Promising Breakthrough Treatment,for Advanced Coronary Artery Disease 2New Phase 3 Study Published in The Lancet Evaluates Efficacy and,Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination,Therapy in Treatment-Experienced Adults With HIV 2New Phase 3 Study Published in The Lancet Evaluates Efficacy and,Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination,Therapy in Treatment-Experienced Adults With HIV 3New Phase 3 Study Published in The Lancet Evaluates Efficacy and,Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination,Therapy in Treatment-Experienced Adults With HIV 4New Phase 3 Study Published in The Lancet Evaluates Efficacy and,Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination,Therapy in Treatment-Experienced Adults With HIV 5New Phase 3 Study Published in The Lancet Evaluates Efficacy and,Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination,Therapy in Treatment-Experienced Adults With HIV 6New Phase 3 Study Published in The Lancet Evaluates Efficacy and,Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination,Therapy in Treatment-Experienced Adults With HIV 7New Phase 3 Study Published in The Lancet Evaluates Efficacy and,Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination,Therapy in Treatment-Experienced Adults With HIV 8
Titanium. Curved 18 mm shafts with 1.5 wide grasping tip. Flat, serrated cross action handle with dull finish.
Titanium. Designed to easily fold the hydroview lens. Will also fold many styles of soft intraocular lenses. Unique cross-action design facilitates folding of the lens.
30 degree angled tip with 45 mm tip opening. Stainless.
Insertion forcep used for the Hydroview lens. Manufactured in titanium.
Medicine Products: